Neupro, the rotigotine transdermal patch developed by Schwarz Pharma for the treatment of early-stage Parkinson's, is now being sold in the UK.
The patch provides consistent and continuous drug delivery over 24 hours and eliminates peaks and troughs in drug levels associated with oral treatment that can lead to fluctuations in symptom control.
Once-a-day dosing is also likely to be more convenient for patients than taking tablets several times a day.
The new dopamine agonist, rotigotine - the active ingredient in Neupro - has a receptor-binding profile that is very similar to naturally occurring dopamine. Clinical trials have shown efficacy and good tolerability in patients with early Parkinson's disease and a potential for long-term benefit. The European Medicines Agency (EMEA) adopted a positive opinion of Neupro in December 2005 and Marketing Authorisation was granted in February 2006.
Schwarz Pharma Ltd, the UK affiliate of the German company, is responsible for sales and marketing of products within the UK and Ireland.